ChemAbout

ChemAbout is a B2B platform where chemical buyers and suppliers discover each other.

Post a purchase requestList your products (for suppliers)
© 2026 ChemAbout
Compound Index|Demand Board|Insights|Exhibitions|Compliance|Help Center|Privacy Policy|Terms of Service|[email protected]
Home/Compounds/API/Boceprevir
C27H45N5O5
528.7 g/mol
API

(1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[(2S)-2-[[1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-yl]carbamoylamino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide

CAS1256751-11-7
Category
API
Compound Class
Peptide
Primary Use
Pharmaceutical Raw Material

This compound is a deuterium-labeled active pharmaceutical ingredient used in pharmaceutical research and manufacturing. Its molecular structure features multiple amide groups and a heterocyclic ring, indicating potential utility as a research tool in drug development.

pharmaceutical research and developmentmanufacturing of active pharmaceutical ingredients

Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.

Sourcing this compound?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→

Related Compounds

ReferenceSame Category

Prochlorperazine edisylate

CAS1257-78-9

pharmaceutical raw material

ReferenceSame Category

Venetoclax

CAS1257044-40-8

pharmaceutical raw material

ReferenceSame Category

11-fluoro dihydroloratadine

CAS125743-80-8

pharmaceutical raw material

ReferenceSame Category

Amikacin hydrate

CAS1257517-67-1

pharmaceutical raw material

Referencestereoisomer of

Boceprevir

CAS394730-60-0

pharmaceutical raw material

Related Reading

Therapeutic Peptides in 2026: This Year's Breakthroughs

2026 has been a concentrated year for peptide therapeutics. Efficacy reached a new high in late-stage trials, the obesity field moved beyond the incretins to amylin, the oral route reached weight management, and peptide-guided radioligand therapy kept advancing — each point tied to a specific 2025–2026 result.

Read more
Identifiers
IUPAC Name

(1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[(2S)-2-[[1,1,1,3,3,3-hexadeuterio-2-(trideuteriomethyl)propan-2-yl]carbamoylamino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide

InChIKey

LHHCSNFAOIFYRV-BHJZPCNUSA-N

SMILES

[2H]C([2H])([2H])C(C([2H])([2H])[2H])(C([2H])([2H])[2H])NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC3CCC3)C(=O)C(=O)N)C2(C)C)C(C)(C)C

Synonyms (2)

—

Sourcing this compound?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→